Lenacapavir

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 315 publications

Current state of HIV treatment

Current state of HIV treatment

Journal: Klinicka mikrobiologie a infekcni lekarstvi
Published: April 07, 2026

HIV/AIDS: MSF condemns Gilead for refusing to sell it lenacapavir.

HIV/AIDS: MSF condemns Gilead for refusing to sell it lenacapavir.

Journal: BMJ (Clinical research ed.)
Published: April 02, 2026

Lenacapavir as pre-exposure prophylaxis for HIV prevention.

Lenacapavir as pre-exposure prophylaxis for HIV prevention.

Journal: The Cochrane database of systematic reviews
Published: April 01, 2026

Lenacapavir-Containing Antiretroviral Therapy in the OPERA Cohort: Patterns of Use and Treatment Outcomes.

Lenacapavir-Containing Antiretroviral Therapy in the OPERA Cohort: Patterns of Use and Treatment Outcomes.

Journal: AIDS patient care and STDs
Published: March 28, 2026

Damaging the conical morphology of HIV-1 capsid by targeting the FG-binding pocket and disfavoring pentameric subunits needed for core closure.

Damaging the conical morphology of HIV-1 capsid by targeting the FG-binding pocket and disfavoring pentameric subunits needed for core closure.

Journal: bioRxiv : the preprint server for biology
Published: March 27, 2026

Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV at 48 Weeks.

Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV at 48 Weeks.

Journal: Journal of acquired immune deficiency syndromes (1999)
Published: March 26, 2026

Lenacapavir prevents production of infectious HIV-1 by abrogating immature virus assembly.

Lenacapavir prevents production of infectious HIV-1 by abrogating immature virus assembly.

Journal: bioRxiv : the preprint server for biology
Published: March 23, 2026

Understanding the clinical implications of the barrier against resistance in antiretroviral treatment.

Understanding the clinical implications of the barrier against resistance in antiretroviral treatment.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 13, 2026

Interactions between long-acting antiretrovirals and opioids: a call for clinical awareness.

Interactions between long-acting antiretrovirals and opioids: a call for clinical awareness.

Journal: Clinical microbiology reviews
Published: March 12, 2026

Mechanistic insights into lenacapavir-induced off-pathway HIV-1 capsid assembly.

Mechanistic insights into lenacapavir-induced off-pathway HIV-1 capsid assembly.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 10, 2026

The "PrEP APPEAL" of less frequent dosing: acceptability of six-monthly long acting-injectable PrEP among gay and other men who have sex with men and transgender women in Asia.

The "PrEP APPEAL" of less frequent dosing: acceptability of six-monthly long acting-injectable PrEP among gay and other men who have sex with men and transgender women in Asia.

Journal: Journal of acquired immune deficiency syndromes (1999)
Published: February 24, 2026

Bridging the Gap: The PrEP Cascade Paradigm Shift for Long-Acting Injectable HIV Prevention.

Bridging the Gap: The PrEP Cascade Paradigm Shift for Long-Acting Injectable HIV Prevention.

Journal: Viruses
Published: February 22, 2026
Showing 1-12 of 315

Last Updated: 04/28/2026